New NNT→Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. https://t.co/O6CC3EXdt6
RT @Brandon_Beaber: A two year study of of rituxan in neuromyelitis optica (NMO). The post-treatment annualized relapse rate is 0.56 which…
A two year study of of rituxan in neuromyelitis optica (NMO). The post-treatment annualized relapse rate is 0.56 which is still quite high and quite concerning to me. In my clinical experience, it is much more effective than this. https://t.co/9qKxqMN84N
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. https://t.co/tRKq2Dz4u4
New NNT→Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. https://t.co/O6CC3EXdt6
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. https://t.co/pjt9xVGm4P